Literature DB >> 12858443

Hepatitis C virus infection in systemic lupus erythematosus: a case-control study.

Gabriel Perlemuter1, Patrice Cacoub, Abdallah Sbaï, Pierre Hausfater, Vincent Thibault, Thi Huong Du Le, Bertrand Wechsler, Catherine Buffet, Jean Charles Piette.   

Abstract

OBJECTIVE: Viruses might be one of the elements that trigger systemic lupus erythematosus (SLE). Steroid therapy may influence the natural history of virus infections. The most frequent extrahepatic manifestations of hepatitis C virus (HCV) including arthralgia, myalgia, sicca syndrome, and antinuclear antibodies, may mimic a connective tissue disease, particularly SLE. Reports on the association between SLE and HCV infection are scarce. We investigated the association of HCV infection and SLE.
METHODS: Retrospective case-control monocentric study of 19 patients with SLE and anti-HCV antibodies versus 42 randomized SLE patients without anti-HCV antibodies, matched for age and sex, coming from our cohort of 700 patients with SLE. SLE and HCV-infection features were reviewed.
RESULTS: Mode of infection was blood product transfusion, drug addiction, or unknown. Prevalence of lupus clinical manifestations, antinuclear, anti-dsDNA, anti-extractable nuclear antigen antibodies, and complement levels was not different between HCV positive and negative SLE patients. Prevalence of cryoglobulin was higher in SLE patients with anti-HCV antibodies (p < 0.04), but none had a mixed cryoglobulinemia syndrome. ALT activity was increased in 11 HCV positive patients and 13 had detectable HCV RNA. Liver biopsy showed cirrhosis in 2 and mild fibrosis and activity in 5. One patient treated with interferon-alpha had a sustained virological response without SLE flare. Steroid therapy did not seem to alter HCV course.
CONCLUSION: SLE in HCV positive patients shows higher prevalence of cryoglobulin without mixed cryoglobulinemia syndrome. HCV infection has moderate signs of biochemical and liver pathological severity. SLE by itself or treated with steroids does not seem to worsen HCV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858443

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

2.  Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.

Authors:  Damien Sene; Valerie Touitou; Bahram Bodaghi; David Saadoun; Gabriel Perlemuter; Nathalie Cassoux; Jean-Charles Piette; Phuc-Le Hoang; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

3.  Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.

Authors:  Jae Hee Lim; Yun Nah Lee; Young Seok Kim; Sang Gyune Kim; Seung Won Jeong; Jae Young Jang; Hong Soo Kim; Sae Hwan Lee; Tae Kwann Park
Journal:  Korean J Hepatol       Date:  2011-03

4.  Network-based study reveals potential infection pathways of hepatitis-C leading to various diseases.

Authors:  Anirban Mukhopadhyay; Ujjwal Maulik
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

5.  Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.

Authors:  Elena Laura Iliescu; Adriana Mercan-Stanciu; Letitia Toma
Journal:  BMC Nephrol       Date:  2020-01-16       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.